Pro-Pharmaceuticals, Inc.'s DAVANAT(R) Prevents Mucositis, a Serious Side Effect of Chemotherapy, in All 100 Cancer Patients Treated

NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (OTCBB: PRWP.OB), today announced that a review of data from its Phase I & II clinical trials show that no mucositis serious adverse events (SAEs) were found in approximately 100 cancer patients that were treated with DAVANAT® and chemotherapy that included 5-FU. For most cancer treatment, about 5-15% of patients get mucositis. However, with 5-FU up to 40% get mucositis, and 10-15% get grade 3-4 oral mucositis. Even in patients with more than 100 cycles of treatments with DAVANAT® and 5-FU, none experienced gastrointestinal (GI) SAEs. SAEs of grade levels 3, 4, 5 result in life threatening events, in-patient hospitalization, persistent or significant disability, or death. 5-FU is one of the most widely used chemotherapy drugs in the world and is used to treat various types of cancers, including colorectal, breast and gastrointestinal.